Loading stock data…
MYGN
$4.80+0.05 (+1.05%)
Market ClosedLast close May 1
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Myriad Genetics, Inc. in the Healthcare sector is trading at $4.80. The stock is currently 44% below its 52-week high of $8.59, remaining 20.5% below its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why MYGN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.80
Potential Upside
5%
Whystock Fair Value$5.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Hold
Mean target$7.42+54.6%
Range$4.00 – $18.00
Fundamentals
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$479.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-107.39%
Volume
Today's trading volume
1.94M
Recent News
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Small-Cap Stocks We Think Twice About
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Tempus AI Expands Strategic Partnership Amid Oncology Boom
TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.
1 Cash-Burning Stock to Target This Week and 2 We Question
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Myriad Genetics And 2 Other Penny Stocks To Watch Closely
The United States market has shown robust growth, rising 3.5% over the last week and 31% over the past year, with earnings expected to increase by 16% annually in the coming years. In such a thriving market, identifying stocks with strong financials becomes crucial for investors seeking both affordability and growth potential. Although often considered a term from bygone eras, penny stocks continue to offer intriguing opportunities within smaller or newer companies that might surprise...